Preliminary results from a recent clinical trial indicate the drug touted by US leaders as a possible treatment offers no significant benefit to patients.
The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.
A leader from the drug research and development company discusses unique problems faced by COVID-19 patients with prior cancer and autoimmune diagnoses.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
As the pandemic maintains its hold, the US agency continues to issue advice and take action related to testing, treatment and information on the virus.
Companies like Biofourmis, THREAD and other virtual tech specialists have seen infusions of funds from investors bullish on decentralized clinical trials.
A recent study from the clinical research services firm indicates the pandemic continues to significantly impact clinical trial sites around the globe.
The US agency continues to issue advice for life-sciences professionals engaged in work related to the virus, and keep an eye out for fraudulent products.
The technology from Opyl uses artificial intelligence to anticipate a COVID-19 treatment, vaccine, diagnostic or device’s chances of success in a study.
Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
The company has released a report revealing how clinical trial professionals are handling start-up, before and after COVID-19 first impacted the industry.
Led by the Spaulding Rehabilitation Hospital, a study by a 60-person task force shows ways mobile health tech can help mitigate the pandemic’s effects.
A leader from the clinical trial patient engagement specialist discusses how clinical trial teams can tackle tricky travel issues in the face of the pandemic.
